Proteins involved in promoting cell proliferation and viability need to be timely expressed and carefully controlled for the proper development of the brain but also efficiently degraded in order to prevent cells from becoming brain cancer cells. A major pathway for targeted protein degradation in cells is the ubiquitin-proteasome system (UPS). Oncoproteins that drive tumor development and tumor maintenance are often deregulated and stabilized in malignant cells. This can occur when oncoproteins escape degradation by the UPS because of mutations in either the oncoprotein itself or in the UPS components responsible for recognition and ubiquitylation of the oncoprotein. As the pathogenic accumulation of an oncoprotein can lead to effectively sustained cell growth, viability and tumor progression, it is an indisputable target for cancer treatment. The most common types of malignant brain tumors in children and adults are medulloblastoma and glioma, respectively. Here, we review different ways of how deregulated proteolysis of oncoproteins involved in major signaling cancer pathways contributes to medulloblastoma and glioma development. We also describe means of targeting relevant oncoproteins in brain tumors with treatments affecting their stability or therapeutic strategies directed against the UPS itself.
INTRODUCTION
Medulloblastoma is the most common malignant brain tumor in children. Around 70% of patients are cured after surgery and radiotherapy; however, survivors often succumb from serious side effects following these treatments.
1 Glioblastoma (GBM) is one of the most lethal of all cancers and also the most common type of primary malignant brain tumors (glioma) in adults. 2 GBM is a WHO grade IV astrocytoma and can either develop de novo without previous diagnosis (primary GBM) or derive and progress into a secondary GBM from an astrocytoma of a lower grade. Other less frequent types of glioma include oligodendroglioma and ependymoma.
In recent years, great strides have been made in characterizing changes in gene expression or genetic and epigenetic alterations associated with the genesis and/or progression of various types of brain tumors. However, less is known about how alterations in protein level and protein activity contribute to brain tumor development. One specific type of post-translational modification is the covalent attachment of a small (8 kDa) and highly conserved protein called ubiquitin (Ub), in a process known as ubiquitylation. 3 Ubiquitylation typically involves (1) the covalent attachment of Ub to a specific protein substrate and (2) the degradation of the polyubiquitylated substrate in a large multisubunit protease complex known as the 26S proteasome. 4 The ubiquitin-proteasome system (UPS) controls diverse cellular processes involving proliferation, maturation, differentiation and cell death. A wealth of recent experimental evidence further demonstrates that deregulation of the Ub system has a causative role in cancer development and progression. In this review, we describe important UPS substrates involved in brain tumor development and the potential premise that protein stabilization can be targeted or that components of the Ub system itself may be attractive candidates for brain cancer therapy.
MEDULLOBLASTOMA BIOLOGY
Recent genomic efforts have divided medulloblastoma into four main molecular subgroups: WNT, SHH (Sonic Hedgehog), Group 3 and Group 4. 5 For all molecular subgroups, there are key medulloblastoma proteins that are characterized as target proteins for the UPS. For example, the WNT (Wingless) pathway substrate b-catenin is regulated by the UPS through the betatransducin repeat-containing E3 Ub protein ligase (beta-TrCP). 6 The beta-TrCP recognition site of the b-catenin gene CTNNB1 is often mutated, leading to b-catenin stabilization in WNT tumors. 5, 7 The SHH tumors show alterations in proteins that lead to SHH pathway activation. For example, the beta-TrCP substrate, GLI family zinc-finger 2 (GLI2), 8 is often elevated and is a marker of poor prognosis for SHH tumors. 9 Furthermore, inactivation of Patched (PTCH) 10, 11 can result in stabilization of the downstream MYCN oncoprotein. 12 Finally, Group 3 and Group 4 tumors often present amplifications in MYC and MYCN, respectively, 13, 14 although MYC protein levels can also be elevated in other tumors without amplifications in MYC genes.
are frequently characterized by loss of chromosome 10 and gain of chromosome 7. Several proteins driving GBM development and progression are direct or indirect targets of the UPS. Receptor tyrosine kinases (RTKs) that are commonly overexpressed or amplified in GBMs including epidermal growth factor receptors (EGFRs), platelet-derived growth factor (PDGF) receptors and MET (encoding the hepatocyte growth factor receptor) are normally targeted for degradation by the CBL proto-oncogene and E3 Ub protein ligase (CBL), and these RTKs often find means to avoid CBL recognition during cancer development. 19 Important downstream kinases including phosphatidylinositol 3'-kinase (PI3K) and the mammalian target of rapamycin (mTOR) are also targets of the UPS. For instance, PI3K is regulated by the Ub ligases CBL-B 20 and F-box and leucine-rich repeat protein 2 (FBXL2), 21 whereas the F-box and WD repeat domain containing 7 (FBW7), E3 Ub protein ligase promotes proteasomal degradation of mTOR. 22 The E3 Ub ligase mouse double minute 2 (MDM2) is a well-established oncoprotein and negative regulator of p53 protein expression. 23 Several other proteins regulated by the UPS that are involved in brain tumor development and progression will be further reviewed below.
THE UPS
Breakdown of proteins (proteolysis) occurs constantly inside cells as the production of new proteins must be balanced by an equal amount of protein degradation for cells to survive. The molecular machinery catalyzing the majority of intracellular protein degradation is known as the UPS. 24, 25 The Ub enzymatic cascade The decoration of protein substrates with chains of Ub molecules is the result of multiple rounds of Ub-conjugation reactions carried out by a three-step enzymatic cascade. First, an E1 enzyme mediates the ATP-dependent activation of Ub. Next, Ub is translocated to an E2-conjugating enzyme, and finally, an E3 Ub ligase facilitates the transfer of Ub to a specific lysine (K) residue on the target substrate ( Figure 1) . 3 The 76-amino-acid Ub polypeptide has seven internal lysines, and Ub chains may be assembled through any of these lysine residues (in addition to the amino group in the N-terminus of Ub). Substrates tagged with K48 or K11-linked polyubiquitin chains are usually destined for proteolytic destruction by the 26S proteasome, 26 whereas substrates conjugated with a single Ub (monoubiquitin) or polyubiquitin chains linked through other lysines in Ub (for example, K63) have non-proteolytic functions modulating various biological processes, such as transcription, DNA replication and repair, among others. 27 Ubiquitylation is counteracted by specific isopeptidases called deubiquitinating enzymes or DUBs, which catalyze the hydrolysis of the peptide bond between the Ub molecule and the substrate, highlighting the reversibility of the Ub system ( Figure 1 ). 28 
E3 Ub enzymes
In the Ub system, substrate specificity is achieved through the use of a large number of different E3s that physically interact with specific target substrates, linking them to the E2 Ub-conjugating enzyme.
29 E3 ligases are encoded by at least 600 human genes, thus exceeding the number of protein kinase genes. 30 The majority of E3s contain a RING (Really-Interesting New Gene)-finger homology domain, which binds to the E2 enzyme and directly mediates the transfer of Ub to the substrate. In contrast, HECT (Homologous to E6-AP C-Terminus) domain E3s form a transient covalent linkage between Ub and a cysteine residue on the E3 prior to transferring the Ub molecule to the bound substrate. 31 RING E3 ligases can be further categorized into single subunit E3s (one protein contains both a RING domain and a substrate-binding domain-for example, MDM2) or multisubunit E3s (for example, Cullin-RING ligases (CRLs)). The CRL is the largest family of E3s and includes the well-described SCF (SKP1-Cullin1-Fbox) and APC/C (anaphase-promoting complex/cyclosome) Ub ligase complexes that have central roles in cell cycle regulation, checkpoint control and genome stability. 32 The APC/C is composed of at least 13 protein subunits and targets numerous cell cycle regulators for proteolysis in mitosis and in G1. The SCF Ub ligases consist of the following four subunits: the RING protein retinoblastoma (RB)X1, the scaffold protein Cullin1, the adapter protein SKP1 and a variable substratebinding component known as the F-box protein. 32 SCF ligases are active throughout the cell cycle, and to date, B70 different F-box proteins have been identified in humans, each likely targeting a unique set of substrates for degradation. 33 Not surprisingly, deregulation of Ub ligases or their target substrates has a causative role in cancer development and progression.
PROTEIN STABILIZATION AND REGULATION BY THE UPS IN BRAIN CANCER
The central nervous system arises from the neural plate, and the brain and the spinal cord later develop from the neural tube of the embryo. Proteins that are involved in early regulation of neuronal embryogenesis include bone morphogenetic proteins, SHH proteins and fibroblast growth factors (FGFs). 34 Other factors essential for normal brain development include the NOTCH family, Figure 1 . Schematic overview of the UPS. Ubiquitylation, or Ubiquitin (Ub) conjugations of protein substrates, is an ATP-dependent reaction that involves a concerted effort of an ubiquitin-activating enzyme (E1), an ubiquitin-conjugating enzyme (E2) and an ubiquitin ligase (E3). In the ubiquitylation process, E3 ligases are the primary sources of substrate specificity, resulting in ubiquitin conjugation to specific lysine (K) residue(s) on the protein substrate. Proteins with K48-linked polyubiquitin chains are degraded by the 26S proteasome complex in an ATPdependent manner, whereas other types of ubiquitin chains (for example, K63) have non-proteolytic functions regulating protein activity. The ubiquitylation process is counteracted by DUBs enzymes that hydrolyze ubiquitin-protein peptide bonds and recycle ubiquitin molecules.
WNT proteins as well as various kinase receptors and their downstream targets, including transcription factors and cell cycle regulators. Several of these proteins are intimately involved in brain tumor formation and cancer progression. Important mechanisms that control oncoprotein stabilization during tumor development have further been discovered when using various animal models of brain tumors (Table 1 ). In the following sections, we will review the recent literature of how the UPS regulates proteins involved in brain tumor biology.
Developmental pathways
The SHH pathway. The Hedgehog pathway is a well-conserved developmental pathway. Hedgehog ligands, such as SHH, act as morphogens during embryogenesis and regulate cell fate and brain patterning. 35 SHH signaling depends on a functional primary cilium-a non-motile microtubule organelle that forms an antenna-like structure on the cell membrane. 36 When SHH binds to the inhibitory receptor PTCH it releases smoothened, leading to the activation of GLI family (GLI1-3) transcription factors. 37 Whereas GLI1 works as an activator of the SHH pathway, both GLI2 and GLI3 can be processed into transcription repressor forms. A speckle-type POZ protein-cullin 3 Ub ligase-promotes ubiquitylation and degradation of GLI2 and GLI3 full-length activators.
38 GLI1 is constitutively active and cannot convert between activator and repressor forms. GLI1 interacts with itchy E3 Ub protein ligase (ITCH)-a member of the HECT family of E3 enzymes. 39 ITCH binds GLI1 and promotes its polyubiqitylation in collaboration with numb homolog (Drosophila) (NUMB)-an adaptor protein that enhances ITCH activity and GLI1 degradation. 39 Interestingly, NUMB expression is attenuated in the SHH group of medulloblastoma consistent with its role in promoting GLI1 degradation. In the absence of SHH, GLI3 is phosphorylated at multiple sites by v-akt murine thymoma viral oncogene homolog 1 (AKT), glycogen synthase kinase 3 beta (GSK3b) and casein kinase 1 (CK1). This leads to direct binding and ubiquitylation by the SCF Ub ligase, SCF b-TrCP and subsequent processing of GLI3 into its transcription-repressor form. 40 It seems like SCF b-TrCP further regulates downstream signaling of the SHH pathway, as GLI2 is also targeted by SCF b-TrCP and then degraded. Gorlin's syndrome is a rare inherited condition with germline mutations in the PTCH gene. It is characterized by an increased incidence of tumors including basal cell carcinoma and medulloblastoma. 10 Interestingly, step-wise loss of PTCH1 during tumor formation and progression in mice leads to stabilization of the MYCN protein 12 ( Table 1) .
The WNT pathway. There are two different WNT pathways: the canonical or the WNT/b-catenin pathway controlling cell-fate determination and the non-canonical pathway regulating cell movement and tissue polarity. 41 SCF b-TrCP negatively regulates the WNT/b-catenin signaling pathway by targeting b-catenin for ubiquitylation following GSK3b-mediated phosphorylation on specific serine/threonine residues in b-catenin at a conserved beta-TrCP-binding motif (degron). 6 These residues are commonly mutated on CTNNB1 in the WNT group of medulloblastoma, 7, 42 resulting in defective degradation of b-catenin 43 because of the failure of beta-TrCP to interact with b-catenin. 44 Similarly, mutationally stabilized CTNNB1 has been valuable in describing how WNT-driven medulloblastoma could be derived from distinct developing brain stem regions (of the lower rhombic lip) in transgenic animals 45 (Table 1) . Mutations in another member of the WNT pathway, the adenomatous polyposis coli (APC) gene, can also lead to stabilization of b-catenin in the development of medulloblastoma in Turcot's syndrome. 46 The NOTCH pathway. NOTCH signaling is involved in the communication between neighboring cells during brain development. 47 Interaction with ligands, DELTA or JAGGED, results in sequential cleavage of NOTCH receptors at the membrane and translocation of the NOTCH intracellular domains into the nucleus, where they serve as transcription factors regulating transcription of various target genes including HES (hairy and enhancer of split) or HES-related (HESR/HEY) transcription factors. 48 The NOTCH pathway is tightly controlled by the UPS system at several levels. 49 and turnover of the unstable NOTCH intracellular domains is mediated by the Ub ligase FBW7 (also known as SEL-10, Ago and CDC4). 50, 51 FBW7 preferentially targets NOTCH intracellular domain phosphorylated by Cyclin C-CDK8 for degradation in the nucleus. 52 The activated NOTCH1 intracellular domain induces SHH group medullobastoma when overexpressed in p53-deficient animals.
53 Surprisingly, NOTCH2 rather than NOTCH1 levels are elevated in tumors generated from this model. As compared with NOTCH1 levels, NOTCH2 levels are also elevated in primary human medulloblastoma. 54 NOTCH1 nuclear staining further correlates with improved outcomes of proneural high-grade glioma. 55 These data may suggest that NOTCH1 activity regulated by UPS is hypothetically necessary for tumor initiation but not for tumor progression.
Kinase receptors and downstream pathways
Receptor tyrosine kinases. RTKs are transmembrane proteins that, upon ligand-binding, dimerize and activate intracellular signaling pathways controlling cell proliferation, survival, migration and differentiation. 56 Signaling via EGFRs (ERBB1-4) is important in controlling cell proliferation and fate during neurogenesis. Signaling via PDGFRA and PDGFRB has important roles both during embryogenesis and in adulthood (reviewed in Andrae et al. 57 ). PDGFRA signaling controls neural stem cell (NSC) fate, inducing the formation of oligodendrocytic rather than neuronal lineage. 58, 59 RTK activity is terminated both by the action of tyrosine phosphatases and by internalization and degradation of the activated receptor. RTK signaling leads to phosphorylation and recruitment of the RING finger E3 Ub ligase CBL 60 (See also Figure 2 ). CBL binds to phosphorylated tyrosine residues on the activated RTK either directly via its tyrosine kinase-binding domain or indirectly through interaction with adapter proteins such as GRB2. CBL ubiquitylates the intracellular part of the activated RTK, and monoubiquitylation at multiple sites serves as a signal for receptor internalization via clathrin-coated pits followed by lysosomal degradation. 61 CBL functions as a negative regulator of many RTKs, including EGFR (ERBB1), ERBB2, PDGFRA and PDGFRB, MET and FGFR (reviewed in Marmor and Yardon 60 ). Activation of oncogenic RTK signaling pathways in glioma can be caused by elevated levels of ligand or increased abundance and activity of receptors. Both PDGF ligands and receptors are found to be overexpressed in glioma 62 often in combination with the loss of p53. 63 The PDGFRA gene is found to be amplified in 13% of GBM. 64 Animal models have indicated that GBM tumors may form by overexpression of PDGFB alone or in combination with the loss of p53. [65] [66] [67] Interestingly, excessive expression of PDGFB ligand causes the formation of brain tumors in mice in a dose-dependent way. 68 In this study, certain untranslated regions are responsible for post-translational modifications of PDGF, and removing these leads to PDGFB protein stabilization ( Table 1) .
The EGFR is found to be overexpressed and amplified in human gliomas, and amplification of the EGFR gene is found in B40% of GBM. 69 The most common EGFR mutant in GBM is EGFRvIII, which lacks the extracellular ligand-binding domain. 70 EGFRvIII is constitutively activated, has a reduced capacity of recruiting CBL and shows reduced receptor internalization and degradation. 71 Overexpression of ERBB2 is found in many tumors, and the ERBB2 gene is found to be mutated in 8% of GBM. 64 Studies in breast tumors have shown that the ERBB2 receptor stabilizes EGFR and inhibits CBL-mediated receptor ubiquitylation by blocking phosphorylation of CBL-and GRB2-binding sites in EGFR. 72 Interestingly, v-erbB, the transforming viral homolog of EGFR, has been found to lack the CBL-binding site, 73 and overexpressing v-erbB from the S100b promoter has been shown to induce oligodendrogliomas in mice. 74 The tyrosine kinase receptor MET is amplified in a smaller fraction of GBMs. 64 In addition, MET is overexpressed in many GBMs 75 in which expression correlates with increasing malignancy grade of the brain tumor. The degradation of activated RTKs can be altered on many levels in human tumors. The activity of CBL is regulated by the tyrosine kinase SRC. Phosphorylation by SRC leads to enhanced autoubiquitylating activity and proteasomal degradation of both CBL and SRC. 76 An alternative degradation mechanism was shown for EGFR in clear cell renal carcinoma, in which polyubiquitylation of the activated RTK by von HippelLindau tumor suppressor, E3 Ub protein ligase leads to proteasomal degradation. 77 Cancer cells have different ways of escaping CBL recognition and avoiding RTK degradation by the UPS. For instance, CBL-binding sites on RTK genes can be mutated, CBL recruitment could become inefficient, degradation of CBL itself could increase or mutations could generate an RTK that will form a fusion protein that escapes proteasomal degradation. 19 The transforming growth factor beta (TGF-b) pathway The TGF-b family of growth factors signals through TGFR1 and TGFR2, activating downstream signaling pathways via phosphorylation of the SMAD family members (SMADs) that when activated function as transcription factors together with various cofactors. Activation of TGF-b signaling results in differential responses, depending on the cellular context. 78 Ubiquitylation of the TGF-b receptors and downstream SMAD effector proteins is regulated by different E3 ligases such as the HECT-type SMAD-specific E3 Ub protein ligase (SMURF) repressing TGF-b signaling and RING-finger domain E3 ligase Arkadia (also known as RNF111) enhancing the TGF-b signal. 79 Indeed, dysregulation of both SMURFs and Arkadia have been found in several types of cancer. 79 Altered TGF-b signaling is found in many diseases and TGF-b is known to promote epithelial-mesenchymal transition in cancer. 80 Normally, TGF-b signaling blocks proliferation by inducing expression of p21 via SMADs and FOXO transcription factors. This is overcome in glioma cells where FOXG1 blocks FOXO and SMAD, and activation of the PI3 kinase pathway leads to phosphorylation of FOXO. 81 TGF-b signaling has also been shown to promote proliferation of glioma cells in cases where the PDGFB gene is unmethylated. The hyperactive TGFb-SMAD pathway here induces PDGFB levels, which correlate to poor prognosis in glioma patients. 82 The DUB USP15 promotes TGFBR1 stability in GBMs by binding to the SMAD7-SMURF2 complex and removing Ubs from TGF-b receptors. Expression of USP15 correlates with high TGF-b activity. Amplifications of USP15 further correlate with poor prognosis in several tumor types including GBMs. 83 The PI3K/PTEN/AKT pathway and mTOR proteins PI3Ks are activated by several different types of membrane receptors, including RTKs, T-cell receptors, integrins, cytokine receptors and G-protein-coupled receptors. The class I PI3K is the best characterized subclass of PI3Ks and is composed of regulatory (p85) and catalytic (p110) subunits. The phosphatase and tensin homolog (PTEN) acts as a phosphatase for phosphatidylinositol (3,4,5)-triphosphate (PIP3), thereby negatively regulating downstream AKT signaling. 84 The mTOR is a serine/threonine kinase that is present in two specific complexes, mTOR complexes 1 and 2 (mTORC1 and mTORC2), which act downstream or upstream of AKT, respectively. The mTOR pathway couples nutrient and energy availability to the execution of various biological processes including cell growth and proliferation, survival, motility, protein synthesis and transcription. 85 The p85 regulatory subunit of PI3K is a substrate for the Ub ligase CBL-B. 86 However, when Cbl-b is knocked out in mouse T cells, ubiquitylation of p85 is not abrogated. Instead, CBL-B loss led to enhanced ubiquitylation of PTEN upon T-cell receptor stimulation. 87 Recently, SCF FBXL2 has further been shown to target p85 for proteasomal degradation. 21 In GBMs, mutations have been found in PIK3R1 and PIK3CA genes that encode regulatory and catalytic subunits of PI3K. 64 The HECT-domain protein NEDD4-1 can regulate PTEN by mono-and polyubiquitylation.
88 Surprisingly, NEDD4-1 is not required for PTEN degradation, as PTEN stability is unaltered in Nedd4-1 knockout mice. 89 Furthermore, a recent study demonstrates that WWP2, a member of the NEDD4-like protein family, interacts with PTEN and stimulates Ub-dependent degradation of PTEN. 90 Loss of heterozygosity on chromosome 10 is a hallmark of many types of tumors including GBMs. PTEN, being situated on this chromosome, is frequently altered in brain tumor cells.
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FBW7 binds a specific phosphodegron in mTOR, promoting its ubiquitylation and proteasomal degradation. 22 This targeting by FBW7 leads to breast cancer suppression in cooperation with PTEN.
22 mTOR and especially the mTORC1/2 complexes are the essential brain tumor pathways. 92 In response to growth factor stimulation, SCF b-TrCP also regulates mTOR activity through the targeted degradation of DEPTOR (DEP domain containing mTORinteracting protein), an inhibitor of both mTORC1 and mTORC2. Figure 2 . A schematic representation of ubiquitin-mediated protein degradation in the key signaling pathways involved in brain tumor development and progression. RTK signaling pathways modulate MYC stability via phosphorylation and dephosphorylation events required for substrate recognition and ubiquitylation by the E3 ligase FBW7. RTK internalization and lysosomal degradation are mediated by E3 ligase CBL. Alternatively, RTKs can be recirculated to the cell surface via early endosomes. In the nucleus, degradation of p53 is regulated by monoand polyubiquitylation carried out by various ubiquitin ligases (not shown). The monoubiquitylated form of p53 is exported to the cytosol, where further polyubiquitylation targets the protein for proteasomal degradation. Phosphorylation of p53 by stress-induced kinases such as ATM disrupts ubiquitylation mediated by MDM2. The activities of both p53 and MYC factors are regulated by shuttling in and out of the nucleus, and proteasomal targeting could take place both within the nucleus and in the cytosol. In the figure, ubiquitin ligases are shown as gray ovals. 104 regulate MYC protein function through nonproteolytic ubiquitylation.
Regulation of MYC activity and stability is a tightly controlled process. ERK or CDKs must first phosphorylate MYC on residue S62. 105 GSK3b needs this priming phosphorylation in order to phosphorylate T58, 96 which can be recognized by FBW7 and degraded first after S62 is dephosphorylated by combined actions of PIN1 prolyl isomerase and the PP2A phosphatase 106 (see also Figure 2 ). However, FBW7-dependent MYC ubiquitylation appears to be more complex, and MYC stability is also controlled by other factors (reviewed in Thomas and Tansley 95 ). The UPS system also controls cellular reprogramming. 107 Depletion of FBW7 results in enhanced reprogramming frequency, whereas inactivation of the DUB PSMD14 abrogates the reprogramming process. The effect of FBW7 loss is designated to the stabilization of MYC that is involved in induced pluripotent stem cell generation. 108 The MYC proteins MYC and MYCN are commonly amplified or overexpressed in brain tumors (for details see the study by Swartling 109 ). Focal high-level amplifications of MYC or MYCN are in most cases mutually exclusive 110 and can occur in both GBM 64 and medulloblastoma. 111 Interestingly, mutations in the histone H3 gene, H3F3A, are commonly found in pediatric GBMs and cause profound upregulation of MYCN. 112 MYC or MYCN is further amplified in almost half of all brain cancers categorized as malignant glioma with PNET-like morphologies. 113 MYCN is downstream of the SHH pathway and is essential for driving SHH-driven brain tumors in various mouse models of medulloblastoma. MYCN overexpression can, together with p53 loss, further drive SHH-dependent medulloblastoma from GPCs following transplantation to the brain. 114 By contrast, overexpressed stabilized forms of its sibling MYC lead to development and progression of SHH-independent aggressive large cell/anaplastic Group 3 medulloblastoma 114, 115 ( Table 1) .
We have recently shown that MYCN can drive aggressive large cell/anaplastic medulloblastoma when overexpressed from the Glutamate transporter 1 promoter in an inducible transgenic model. 116 We further showed that MYCN carrying a stabilizing FBW7 degron mutation (T58A) was necessary for brain tumor generation from NSCs 117 ( Table 1) . By transducing forebrain NSCs with MYCN-T58A, we could mimic malignant glioma with PNET-like morphologies 113 or pediatric GBMs that are shown to depend on high levels of MYCN. 112 Interestingly, depending on the timing of MYCN induction, both SHH-dependent-and -independent medulloblastoma types formed from cerebellar NSCs despite using the same stabilized MYCN oncoprotein.
p53. The transcription factor p53 is a tightly regulated sensor of cellular stress and its activation might result in cell cycle arrest, apoptosis, senescence, DNA repair, altered metabolism or autophagy. 118 Under normal conditions, protein levels of p53 are held low by proteasomal degradation, promoted in part through continuous targeting by the RING finger E3 Ub ligase MDM2. 23 Specifically, the transcription of MDM2 is upregulated by p53, creating a feedback loop where MDM2 targets both p53 and itself for proteasomal degradation.
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MDM2 also blocks the transactivating activity of p53, preventing transcriptional activation of p53 target genes. 120 The MDM2 protein can either homo-or heterodimerize with the homologous RING finger protein MDM4 (also known as MDMX) (Figure 2 ). MDM4 binds p53; however, it has no intrinsic Ub ligase activity. 121 The MDM2/p53 interaction and subsequent ubiquitylation is inhibited by various post-translational modifications including phosphorylation, acetylation, neddylation and sumoylation.
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MDM2 can either monoubiquitylate p53, facilitating transport to the cytoplasm or cooperate with MDM4 and other Ub ligases to polyubiquitylate, and thereby target p53 for degradation by the proteasome. 123 Several p53-targeting Ub ligases with complementing functions have been discovered lately, although MDM2 seems to be the main factor regulating p53 levels under normal conditions. 124 For example, the E3 ligase PIRH2 (p53-induced protein with RING-H2 domain) targets phosphorylated p53 during DNA damage 125 ( Figure 2 ). UBE4B is another Ub ligase that interacts with both MDM2 and p53. UBE4B is found to be amplified and overexpressed in brain tumors, and its expression is inversely correlated to levels of p53. 126 Whereas mutations and loss of heterozygosity of p53 are commonly found in human secondary GBMs, the primary GBM more often displays upstream inactivation of the p53 pathway through amplification and overexpression of MDM2 or deletion of Ink4a/Arf. 69 Recent results from the The Cancer Genome Atlas showed that altered p53 signaling was found in 87% of GBM, with amplification of MDM2 in 14% and inactivation of alternate reading frame (ARF) of the CDKN2A gene by deletion or mutation in 49% of the cases. 64 p53 status is an important risk factor in SHH medulloblastoma subtypes despite the fact that the majority of human medulloblastoma, including Groups 3 and 4, lack p53 mutations.
127 MDM2 can be involved in regulating p53 levels in these tumors, as the MDM2 protein is often overexpressed predominantly in medulloblastoma cells where the p53 gene is not mutated. 128 Cell cycle proteins. The intricate interplay between different E3s is of major importance for the timely activation/inactivation of various CDK regulatory proteins (for example, CDK inhibitors and cyclins). SCF ligases target numerous cell cycle regulatory proteins for degradation. SCF SKP2 recognizes p27 phosphorylated by Cyclin E-CDK2, an interaction which also depends on the co-factor CKS1. 129 Degradation of p27 results in elevated Cyclin E-CDK2 activity, entry into the S-phase and initiation of DNA replication. As CDK activity rises in G1, the RB pocket proteins (RB, p107 and p130) are inactivated by phosphorylation and E2F factors are released. Several different Ub ligases target E2F1 for proteasomal degradation, including SKP2 at the end of the S-phase 130 and APC/ C in the prometaphase. 131 The APC/C ligase controls both positive and negative regulators of the cell cycle through association with its co-activator subunits, CDC20 and CDH1, which determine substrate specificity. 132 These differences in substrate specificity have important roles during neurogenesis, (reviewed by Puram and Bonni 133 ), where, for example, APC/C together with CDH1 target ID proteins, regulating cell cycle exit. 134 CDKs are often amplified or overexpressed in both glioma and medulloblastoma (for a more detailed review on this, see Vlachostergios et al.
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). The CDK inhibitor p27 is downregulated and associated with increased glioma grade, 136 and SKP2 (that controls p27 degradation) is found at elevated levels in high-grade glioma. In addition to FBW7, the Ub ligase PARK2 also targets Cyclin E for degradation and is commonly found to be mutated in GBMs with increased Cyclin E stability 137 (Table 1) . Almost 80% of GBM tumors display alterations in the RB pathway. The RB gene itself is found to be mutated or deleted in B10% of the cases, whereas CDKN2A and CDKN2B are deleted or mutated in 52 and 47% of GBMs, respectively. 64 RB interacts with APC/C that controls genomic stability by regulating proteins controlling the mitotic spindle formation checkpoint. Several APC/ C targets, including CDC20, polo-like kinase 1, Aurora kinases, SKP2, UBE2C and survivin are overexpressed in brain tumors. 138 EMI1 is a transcriptional target of E2F1 that inhibits APC/C Cdh1 function. Overexpression of EMI1 accelerates S-phase entry and leads to chromosomal instability. 139 EMI1 is found to be overexpressed in ependymomas and high-grade gliomas. Loss of RB leads to dysregulation of EMI1 and genomic instability in human tumors, including oligodendrogliomas.
140 EMI1 is further regulated by beta-TrCP and fibroblasts from mice lacking betaTrCP show decreased genetic stability and mitotic progression in part owing to the accumulation of EMI1. 141, 142 NFkB. NFkB signaling controls diverse physiological functions including cell growth and survival, differentiation, development, immunity and inflammation. 143 In unstimulated cells, NFkB proteins are generally kept inactive through binding to proteins known as inhibitors of NFkB (IkBs). 144 The NFkB pathway is subjected to tight post-translational regulation controlled by protein kinases, DUBs 145 and Ub ligases. Phosphorylation of IkBa by IKK targets this inhibitor for ubiquitylation and proteasomal degradation by the SCF b-TrCP Ub ligase, allowing the NFkB protein RelA to translocate to the nucleus and activate gene expression. SCF b-TrCP also contributes to NFkB pathway activation by promoting the formation of specific NFkB protein complexes in the nucleus through ubiquitylation and partial proteolysis of IkBs, such as p105 and p100. Furthermore, we and others have recently demonstrated that the SCF FBW7 Ub ligase targets p100 for degradation in a GSK3b-dependent manner. [146] [147] [148] In this context, NFkB pathway activity is modulated by both SCF FBW7 and SCF b-TrCP . The IkBa gene NFKB1A is often heterozygously deleted in nonclassical subtypes of GBM patients, 149 suggesting an active role for the NFkB pathway in these brain tumors. NFkB activity is higher in GBMs as compared with the normal brain; 150 however, the mechanism of NFkB activation in GBMs is largely undefined perhaps because of the large heterogeneity of these tumors. However, NFkB could putatively be activated by cytokines such as TNF-alpha or interleukins that are secreted by activated tumorassociated macrophages. 151 The regulation of NFkB by the UPS is further discussed below.
TARGETING UPS SUBSTRATES OR THE UPS ITSELF IN FUTURE CANCER THERAPIES
Malignant high-grade brain tumors have a dismal prognosis, and resistance-associated mechanisms to chemotherapies often preclude the complete eradication of cancer cells resulting in tumor relapse. With this follows the challenge of developing novel therapeutic strategies targeting the key proteins contributing to tumor cell resistance and/or exploring new classes of drug targets. Recently, with the discovery of the proteasome inhibitor Bortezomib (PS341/Velcade), the UPS has matured as an important drug discovery arena with Ub enzymes as the prime candidate drug targets. 152 As outlined above, many proteins directly influencing brain tumor development and progression are substrates of the UPS. We will now exemplify how such substrates or various components of the UPS could be targeted in brain tumors.
Targeting substrates of the UPS Developmental pathways. Long-term treatment with the smoothened inhibitor cyclopamine results in complete disruption of glioma stem cell populations. Besides inhibiting smoothened, there are now ways to target GLI proteins downstream of SHH signaling. 153 Of the GLIs, GLI2 is supposedly the most important therapeutic target in medulloblastoma. 154 It is not completely clear how GLI2 stabilization is regulated in tumors. Interestingly, arsenic treatment has been effective in targeting GLI2 in SHH-dependent tumors, as it destabilizes GLI2 and prevents ciliary accumulation. 155 Inhibition of b-catenin by methylseleninic acid is also a result of increased protein degradation.
156 Surprisingly, in some cancer cells this process is not dependent on GSK-3b phosphorylation that normally regulates b-catenin protein stability.
PI3K, mTOR and MYC proteins. MYCN is indirectly stabilized by the activation of PI3K. 157 Blockade of PI3K leads to decreased MYCN protein levels in neuroblastoma-a childhood tumor with frequent MYCN amplifications. 158 mTOR inhibitors are also effective in suppressing MYCN in neuroblastoma 159 or inhibiting MYC in murine medulloblastoma. 115 Furthermore, a dual inhibition of PI3K and mTOR shows emergent efficacy when targeting human glioma cells. 160 Stabilization of MYCN by Aurora A kinase is controlled by FBW7 in neuroblastoma, 161 and MYCN protein stabilization is found in a large set of patients who lack MYCN amplifications. 15 Small Aurora A kinase inhibitors can disrupt the binding of Aurora-A to MYCN and allow FBW7 to recognize and promote the degradation of MYCN. 162 Therapeutic MYCN depletion totally cures tumors in transgenic mouse models of brain tumors, 116 and the depletion of all MYC proteins also cures tumors driven by other oncogenes, 163 highlighting MYC proteins as indisputable targets for tumor treatment. 164 Targeting UPS components. Inhibition of proteasomal activity using reversible (Bortezomib) or irreversible (Carfilzomib) protease inhibitors has remarkable efficiency against multiple myeloma 165, 166 but also demonstrates potency for the treatment of different types of lymphomas and is currently undergoing clinical trials for the treatment of many other malignancies, including pediatric and adult brain tumors. 167, 168 Proteasomal inhibitors induce cell cycle arrest and apoptosis. However, the molecular mechanism(s) is still not clear and various factors seem to be important in different cell types. Treatment with proteasomal inhibitors can shift cellular homeostasis towards apoptosis by causing an accumulation of pro-apoptotic proteins such as BID and BAX. 169, 170 Proteasomal inhibitors can also reduce the expression of anti-apoptotic proteins of the BCL2 or inhibitor of apoptosis families possibly through the inactivation of NFkB transcriptional activity following stabilization of the IkB. In medulloblastoma, Bortezomib has been reported to trigger reactive oxidative stress (ROS)-associated apoptosis by stabilizing the pro-apoptotic protein NOXA. 171 However, as proteasomal inhibitors work non-selectively blocking the degradation of all proteins passing through the 26S proteasomal machinery, more specific drugs are needed ( Figure 3 ). In fact, despite a strong scientific rationale for using Bortezomib as an additional therapy in patients with recurrent GBM, this combination is clinically ineffective. 167 Therefore, targeting the enzymes regulating the ubiquitylation process is an alternative and more specific approach, possibly also with less unwanted side effects (Figure 3) . Inhibitors of E1 and E2 enzymes have been reported; however, their potential clinical efficiency remains to be demonstrated. In addition, targeting E1 or E2 enzymes could also result in undesirable effects on normal cells, as they are expected to inhibit most or many E3 ligases. Targeting the E1-activating enzyme (NAE-E1) for the Ub-like protein NEDD8 is a more specific approach because the primary targets for neddylation appears to be CRLs. Neddylation of the cullin component is critical for CRL activity, and inhibitors of NAE-E1 could thus preferentially block CRLs. Indeed, MLN4924-a small molecule inhibitor of the NAE-E1 enzyme-has been developed and shows promise as an anticancer drug in mouse models and preclinical studies. 172, 173 Targeting specific E3 Ub ligases directly. Higher specificity is achieved if the activity of single E3s or DUBs is blocked. These enzymes are particularly attractive drug targets, as they are responsible for mediating ubiquitylation/deubiquitylation of protein substrates frequently dysregulated in tumor cells. In particular, many E3s/DUBs qualify as drug targets because they are overexpressed in human tumors and are often associated with the suppression of multiple tumor-suppressor proteins. Although the development of DUB inhibitors is still in its infancy, several compounds are under development. 152 Multiple strategies can be envisioned for targeting E3 Ub ligases, including development of small molecules that impair the binding between the E3 ligase and the E2 enzyme, or between the E3 and its specific target substrate(s). In principle, compounds that induce a conformational change in the E3 could attenuate Ub ligase stability and/or interfere with E3 activity. Nucleic acids (for example, micro RNA, small interfering RNA) that reduce the expression of the E3 ligase, or antibodies/peptides that interfere with E3 subcellular localization or activity, represent other possibilities to inhibit oncogenic E3s. Finally, it should be emphasized that there is tight interplay between protein ubiquitylation and protein phosphorylation, and understanding how these systems cooperate in controlling the stability and activity of proteins deregulated in cancer cells are important areas of future research.
MDM2. MDM2, the major regulator of p53 protein, has strong clinical relevance in brain tumors with a functional p53 gene. Several compounds have been developed aiming to restore p53 activity in tumors by interfering with the p53-MDM2 interaction. Nutlins are one example of low molecular weight compounds that target the p53-binding pocket of MDM2. By preventing the interaction of MDM2 with p53, the levels of p53 are increased, leading to cell cycle arrest and apoptosis in tumor cells with wildtype p53. 174 An alternative approach involves targeting MDM4 to achieve destabilization of MDM2 and induction of a p53 response. 175 Efforts have also been made to develop molecules directed towards p53. The compound RITA induces apoptosis in tumor cells by binding the N-terminal domain of p53, which inhibits its interaction with MDM2. 176 However, these drugs will only induce a p53 response in tumor cells expressing wild-type p53 protein. Depending on the mechanism of p53 inactivation, alternative approaches are warranted. Prima-1 is one example of a small molecule that causes a conformational change in mutated p53, restoring the wild-type-like conformation and inducing an apoptotic response.
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SKP2. Given that SKP2 is overexpressed in a large number of malignancies and, as outlined above, targets preferentially tumor-suppressor proteins important for cell division control, including p27, p21, p57 and p130, makes it an appealing drug target. 178 The oncogenic function of SKP2 is underscored by the inverse association with p27 protein level in medulloblastoma 179 and glioma. 136 A schematic overview of SKP2 and its potential substrates in brain tumors is presented in Figure 4 . SKP2 mRNA levels are elevated both in medulloblastoma and GBM as compared with the normal brain (Figure 4) , indicating SKP2 as a promising drug target in these types of tumors. Small molecule inhibitors of SCF SKP2 have been discovered, including a compound that prevents the binding of SKP2 to the core ligase, triggering the accumulation of p27 and cell cycle arrest and can apparently even overcome Bortezomib resistance. 180 Recently, inhibitors that selectively target the interaction between SKP2 and CKS1 as well as its substrate p27 have also been identified 181 and could thus be useful for treating tumors with deregulation of the SKP2-p27 axis. Another report shows how a novel SKP2-specific inhibitor directly binds the F box motif of SKP2, 182 leading to an effective block of SKP2-SKP1 interactions and suppression of SKP2 ligase activity. This novel SKP2 inhibitor effectively inhibits tumor cell proliferation, survival and glycolysis and is involved in triggering p53-independent senescence in various animal cancer models.
Beta-TrCP. As outlined above, SCF b-TrCP triggers the ubiquitylation of several different proteins involved in brain tumor development and/or progression, including GLI2, b-catenin as well as the NFkB inhibitor, IkBa 183 ( Figure 4) . Thus, targeting beta-TrCP might be a promising approach in GBM suppression. Indeed, an inhibitor that suppresses IkBa ubiquitylation, but not Figure 3 . Various ways to target the UPS in brain tumors. Apart from targeting E1 and E2 enzymes directly, there are ways to target the E1-activating enzyme for the ubiquitin-like protein NEDD8, which will specifically inhibit the ubiquitin-ligase activity of Cullin-Ring ubiquitin ligases (CRLs) such as SKP2 as depicted. Even more specific ways to target UPS are by targeting specific DUBs or E3 ligases, for example, by using inhibitors directed against SKP2 or by substrate interaction inhibitors, such as nutlins, that interferes with the p53-MDM2 interaction. A broader therapeutic approach involves using proteasome inhibitors that are currently evaluated in various brain tumor therapies.
phosphorylation, has been identified. 184 This could prove promising in restoring IkBa levels, as mutated alleles of NFKB1A were rarely found in the heterozygously NFKB1A-deleted GBMs. 149 Interestingly, NFKB1A and EGFR amplifications were mutually exclusive, suggesting that these events connect in a similar oncogenic pathway. 149 Judging from beta-TrCP mRNA levels, SCF b-TrCP is suppressed in GBM patients (Figure 4) . Elevation of SCF b-TrCP expression is instead observed in medulloblastoma, where NFKB1A deletions have only been found in Group 4 tumors 42 ( Figure 4 ). This tumor-specific difference is interesting and could suggest that SCF b-TrCP controls the stability of distinct oncoproteins in one brain tumor type as compared with another.
FBW7. FBW7 is an important oncoprotein suppressor and is frequently inactivated by mutation, deletion and promoter hypermethylation in multiple malignancies. 185 However, the role of FBW7 in brain tumorigenesis is not fully understood. FBW7 is found to be downregulated in human gliomas 186 ( Figure 4) . Loss of FBW7 in p53/PTEN-deficient NSCs can further promote glioma formation by MYC stabilization 187 (Table 1) . However, abrupt accumulations of FBW7 substrates such as MYC, c-JUN and NOTCH1 could also enforce cell death by apoptosis. 188, 189 In fact, loss of FBW7 has been shown to drive normal brain cells into apoptosis. 190, 191 How FBW7-deficient tumor cells evade apoptosis is still unclear; however, one possibility is that the accumulation of FBW7 substrates with pro-survival functions (for example, MCL1 and NFkB2) protects cancer cells from cell death. Indeed, there is an intimate association between inactivation of the tumorsuppressor FBW7 and drug resistance. 192 However, whereas FBW7-deficient cells are resistant to some antitumor agents, FBW7 inactivation might sensitize tumor cells to other drugs. 193 Interestingly, in chronic myelogenous leukemia-initiating cells, 194 a sudden FBW7 loss restrains tumorigenesis. There, FBW7 suppression increases the stabilization of MYC, thereby promoting p53-dependent apoptosis. 188 In principle, these results suggest that specific FBW7 inhibitors could potentially be used to force non-dividing cancer cells to proliferate, thus increasing their sensitivity to conventional therapeutic drugs. Overall, FBW7 levels are low in both MB and GBM (Figure 4) as compared with the normal brain, suggesting that FBW7 expression is suppressed (at least to some extent) during development or progression of specific types of tumors. Whether targeting 196 were preprocessed together using the RMA algorithm 197 implementation in the ExpressionFileCreator module on the GenePattern analysis platform. 198 Distributions of SKP2 (top), BTRC (middle) and FBXW7 (bottom) expression values in normal and tumor sets, respectively, are depicted as box-and-whisker-plots, with the median of expression represented by horizontal lines inside each box, lower and upper box borders, indicating 25th and 75th percentiles, respectively-regions between whiskers including all non-outlier values and dots representing outliers. Right panel: raw expression data for 62 medulloblastoma samples 13 and 9 hindbrain (cerebellum) samples 196 were preprocessed and illustrated as above. Po0.01 for all six comparisons using two-tailed Welch's t-test statistics. Figures were generated in MATLAB.
FBW7-deficient brain tumors with drugs directed towards specific FBW7 substrates could open up new therapeutic windows remains to be shown.
CONCLUSIONS AND FUTURE PERSPECTIVES
UPS has important functions in normal brain development controlling cell fate and specification. The accumulation of reports describing dysregulated UPS components in cancer suggests that increased protein stabilization of oncoproteins or destabilization and degradation of tumor-suppressor proteins is important for brain tumor development. Degradation of stabilized oncoproteins or restoration of destabilized suppressors could prove to be effective in inhibiting tumor cells. Thus, the UPS regulates many substrates that partake in brain cancer and is an unquestionable therapeutic target for brain tumor treatment. Notably, brain tumors have recently been divided into specific subgroups depending on their genetic profiles and their molecular biology, implying that individual tumors depend on distinct sets of cancer proteins. We have described that the most common types of malignant brain tumors including medulloblastoma and glioma and their defined subgroups have distinct amplifications or deletions in well-known UPS substrates. In summary, it is clear that the UPS has an important role in brain tumorigenesis, and specific targeting of this system shows promise for treating these devastating brain tumors.
